Form 4 for STLN Starling Oncology, Inc.
Accepted 2025-11-14 00:00:00 ET · period of report 2025-11-12 · accession 0001079973-25-001765 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-14 | 2025-11-12 | STLN | Virnich Daniel | CEO | A - Grant | $0.00 | +6,211 | 1.79M | +0.3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-12 | A | A | 6,211 | $0.00 | 1,793,520 | D | — | — | (F1) Represents RSU awards that were fully vested upon grant, net of withholding tax obligations. |